Literature DB >> 19504188

Structure-activity relationships of tariquidar analogs as multidrug resistance modulators.

Ilza K Pajeva1, Michael Wiese.   

Abstract

The review summarizes the most recent achievements in structure-activity relationship (SAR) studies of tariquidar and its analogs. Tariquidar is one of the most promising representatives of the third generation of multidrug resistance (MDR) modulators created so far. This fact determines the strong interest of different research groups in the development of tariquidar-like structures as selective inhibitors of MDR transporters in resistant human cancer cells. After the discovery of tariquidar, a number of analogs have been synthesized and pharmacologically tested, thus supplying good data for comprehensive analyses of their structure-activity relationships. In the review, the structural and pharmacological data of newly synthesized tariquidar-like compounds are first presented. Next, the main achievements in the SAR studies are described focusing on two main transport proteins: P-glycoprotein and breast cancer resistance protein. The reported results are discussed from the point of view of their significance and importance for future directions in the rational design of effective MDR modulators.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19504188      PMCID: PMC2758111          DOI: 10.1208/s12248-009-9118-z

Source DB:  PubMed          Journal:  AAPS J        ISSN: 1550-7416            Impact factor:   4.009


  46 in total

Review 1.  Multidrug resistance reversal agents.

Authors:  Jacques Robert; Christian Jarry
Journal:  J Med Chem       Date:  2003-11-06       Impact factor: 7.446

2.  Structure-function relationships of multidrug resistance P-glycoprotein.

Authors:  Ilza K Pajeva; Christoph Globisch; Michael Wiese
Journal:  J Med Chem       Date:  2004-05-06       Impact factor: 7.446

Review 3.  Structural, mechanistic and clinical aspects of MRP1.

Authors:  D R Hipfner; R G Deeley; S P Cole
Journal:  Biochim Biophys Acta       Date:  1999-12-06

Review 4.  An inventory of the human ABC proteins.

Authors:  I Klein; B Sarkadi; A Váradi
Journal:  Biochim Biophys Acta       Date:  1999-12-06

Review 5.  Overcoming multidrug resistance in cancer: an update on the clinical strategy of inhibiting p-glycoprotein.

Authors:  Hilary Thomas; Helen M Coley
Journal:  Cancer Control       Date:  2003 Mar-Apr       Impact factor: 3.302

6.  Potent and selective inhibitors of breast cancer resistance protein (ABCG2) derived from the p-glycoprotein (ABCB1) modulator tariquidar.

Authors:  Matthias Kühnle; Michael Egger; Christine Müller; Anne Mahringer; Günther Bernhardt; Gert Fricker; Burkhard König; Armin Buschauer
Journal:  J Med Chem       Date:  2009-02-26       Impact factor: 7.446

7.  Pheophorbide a is a specific probe for ABCG2 function and inhibition.

Authors:  Robert W Robey; Kenneth Steadman; Orsolya Polgar; Kuniaki Morisaki; Margaret Blayney; Prakash Mistry; Susan E Bates
Journal:  Cancer Res       Date:  2004-02-15       Impact factor: 12.701

8.  Inhibition of P-glycoprotein function by XR9576 in a solid tumour model can restore anticancer drug efficacy.

Authors:  J Walker; C Martin; R Callaghan
Journal:  Eur J Cancer       Date:  2004-03       Impact factor: 9.162

9.  Pumping of drugs by P-glycoprotein: a two-step process?

Authors:  Thomas Litman; Torben Skovsgaard; Wilfred D Stein
Journal:  J Pharmacol Exp Ther       Date:  2003-10-08       Impact factor: 4.030

10.  The multidrug-resistant phenotype associated with overexpression of the new ABC half-transporter, MXR (ABCG2).

Authors:  T Litman; M Brangi; E Hudson; P Fetsch; A Abati; D D Ross; K Miyake; J H Resau; S E Bates
Journal:  J Cell Sci       Date:  2000-06       Impact factor: 5.285

View more
  6 in total

1.  3D-QSAR AND CONTOUR MAP ANALYSIS OF TARIQUIDAR ANALOGUES AS MULTIDRUG RESISTANCE PROTEIN-1 (MRP1) INHIBITORS.

Authors:  Prathusha Kakarla; Madhuri Inupakutika; Amith R Devireddy; Shravan Kumar Gunda; Thomas Mark Willmon; K C Ranjana; Ugina Shrestha; Indrika Ranaweera; Alberto J Hernandez; Sharla Barr; Manuel F Varela
Journal:  Int J Pharm Sci Res       Date:  2016-02-01

2.  A pharmacodynamic study of docetaxel in combination with the P-glycoprotein antagonist tariquidar (XR9576) in patients with lung, ovarian, and cervical cancer.

Authors:  Ronan J Kelly; Deborah Draper; Clara C Chen; Robert W Robey; William D Figg; Richard L Piekarz; Xiaohong Chen; Erin R Gardner; Frank M Balis; Aradhana M Venkatesan; Seth M Steinberg; Tito Fojo; Susan E Bates
Journal:  Clin Cancer Res       Date:  2010-11-16       Impact factor: 12.531

Review 3.  Recent advances in the search of BCRP- and dual P-gp/BCRP-based multidrug resistance modulators.

Authors:  Silvia Dei; Laura Braconi; Maria Novella Romanelli; Elisabetta Teodori
Journal:  Cancer Drug Resist       Date:  2019-09-19

4.  Reversal of MRP7 (ABCC10)-mediated multidrug resistance by tariquidar.

Authors:  Yue-Li Sun; Jun-Jiang Chen; Priyank Kumar; Kang Chen; Kamlesh Sodani; Atish Patel; Yang-Lu Chen; Si-Dong Chen; Wen-Qi Jiang; Zhe-Sheng Chen
Journal:  PLoS One       Date:  2013-02-05       Impact factor: 3.240

5.  Insights into P-Glycoprotein Inhibitors: New Inducers of Immunogenic Cell Death.

Authors:  Joanna Kopecka; Martina Godel; Silvia Dei; Roberta Giampietro; Dimas Carolina Belisario; Muhlis Akman; Marialessandra Contino; Elisabetta Teodori; Chiara Riganti
Journal:  Cells       Date:  2020-04-22       Impact factor: 6.600

Review 6.  Perplexing Role of P-Glycoprotein in Tumor Microenvironment.

Authors:  Kianna Robinson; Venkataswarup Tiriveedhi
Journal:  Front Oncol       Date:  2020-03-05       Impact factor: 6.244

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.